Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diet, Protein-Restricted | 9 | 2024 | 80 | 3.680 |
Why?
|
| Insulin Resistance | 9 | 2022 | 669 | 3.150 |
Why?
|
| Polycystic Ovary Syndrome | 4 | 2022 | 71 | 2.640 |
Why?
|
| Glucose Intolerance | 5 | 2022 | 83 | 2.430 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2024 | 229 | 1.750 |
Why?
|
| Reproduction | 2 | 2025 | 216 | 1.520 |
Why?
|
| Phenols | 3 | 2025 | 64 | 1.410 |
Why?
|
| Endocrine Disruptors | 2 | 2025 | 53 | 1.310 |
Why?
|
| Benzhydryl Compounds | 2 | 2025 | 72 | 1.300 |
Why?
|
| Glucose | 5 | 2023 | 842 | 1.000 |
Why?
|
| Muscle, Skeletal | 5 | 2024 | 979 | 0.900 |
Why?
|
| Hyperandrogenism | 3 | 2022 | 22 | 0.870 |
Why?
|
| Ovary | 3 | 2021 | 358 | 0.800 |
Why?
|
| Rats | 15 | 2024 | 3387 | 0.790 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 1354 | 0.790 |
Why?
|
| Androgens | 3 | 2022 | 270 | 0.760 |
Why?
|
| Rats, Wistar | 6 | 2024 | 306 | 0.750 |
Why?
|
| Endocrinology | 1 | 2023 | 128 | 0.700 |
Why?
|
| Paternal Age | 1 | 2020 | 16 | 0.660 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2017 | 51 | 0.640 |
Why?
|
| Fathers | 1 | 2020 | 70 | 0.630 |
Why?
|
| Fetal Development | 1 | 2021 | 126 | 0.620 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 76 | 0.600 |
Why?
|
| Folic Acid | 2 | 2019 | 277 | 0.590 |
Why?
|
| Insulin | 3 | 2022 | 1131 | 0.580 |
Why?
|
| Oocytes | 4 | 2022 | 278 | 0.580 |
Why?
|
| Vitamin B Complex | 2 | 2019 | 39 | 0.570 |
Why?
|
| Pregnancy | 17 | 2024 | 7404 | 0.570 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2017 | 74 | 0.550 |
Why?
|
| Animals | 23 | 2025 | 33120 | 0.520 |
Why?
|
| Testosterone | 4 | 2020 | 600 | 0.500 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2547 | 0.490 |
Why?
|
| Thinness | 1 | 2016 | 69 | 0.470 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2015 | 14 | 0.460 |
Why?
|
| Estradiol | 2 | 2020 | 476 | 0.450 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 16 | 0.450 |
Why?
|
| Signal Transduction | 4 | 2017 | 4468 | 0.450 |
Why?
|
| Insulin-Secreting Cells | 2 | 2015 | 132 | 0.440 |
Why?
|
| Receptors, Estrogen | 3 | 2013 | 714 | 0.430 |
Why?
|
| Benzopyrans | 3 | 2013 | 22 | 0.420 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 402 | 0.420 |
Why?
|
| Female | 27 | 2025 | 67915 | 0.420 |
Why?
|
| Maternal Exposure | 1 | 2015 | 145 | 0.410 |
Why?
|
| Mitochondria | 5 | 2023 | 731 | 0.410 |
Why?
|
| Receptors, Prostaglandin | 2 | 2013 | 14 | 0.400 |
Why?
|
| Glucose Tolerance Test | 3 | 2020 | 199 | 0.390 |
Why?
|
| Estrogen Receptor beta | 4 | 2013 | 81 | 0.370 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2012 | 8 | 0.370 |
Why?
|
| Blood Glucose | 2 | 2015 | 1087 | 0.360 |
Why?
|
| Progesterone | 2 | 2012 | 430 | 0.330 |
Why?
|
| Neutrophils | 1 | 2012 | 350 | 0.320 |
Why?
|
| Estrogen Receptor alpha | 4 | 2013 | 419 | 0.310 |
Why?
|
| Adrenomedullin | 2 | 2023 | 72 | 0.290 |
Why?
|
| Stilbenes | 1 | 2006 | 37 | 0.250 |
Why?
|
| Hypertension | 1 | 2014 | 1289 | 0.250 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 413 | 0.250 |
Why?
|
| DNA, Mitochondrial | 3 | 2024 | 239 | 0.250 |
Why?
|
| Estrogen Antagonists | 1 | 2006 | 94 | 0.240 |
Why?
|
| Mitochondrial Dynamics | 2 | 2024 | 49 | 0.240 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1128 | 0.240 |
Why?
|
| Fluorocarbons | 1 | 2025 | 61 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 477 | 0.220 |
Why?
|
| Estrogens | 1 | 2006 | 424 | 0.210 |
Why?
|
| Embryonic Development | 1 | 2025 | 212 | 0.200 |
Why?
|
| Sex Factors | 2 | 2017 | 1294 | 0.200 |
Why?
|
| Labor, Induced | 2 | 2013 | 30 | 0.180 |
Why?
|
| Cervix Uteri | 2 | 2013 | 64 | 0.180 |
Why?
|
| Uterus | 4 | 2012 | 533 | 0.180 |
Why?
|
| Diabetes, Gestational | 1 | 2023 | 108 | 0.180 |
Why?
|
| Sex Differentiation | 1 | 2021 | 16 | 0.170 |
Why?
|
| Male | 9 | 2025 | 62089 | 0.170 |
Why?
|
| Mice, Obese | 1 | 2020 | 73 | 0.170 |
Why?
|
| Fasting | 1 | 2022 | 300 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2023 | 317 | 0.160 |
Why?
|
| Humans | 13 | 2025 | 126089 | 0.160 |
Why?
|
| Infertility, Female | 1 | 2021 | 144 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2024 | 763 | 0.160 |
Why?
|
| Adenosine Triphosphate | 1 | 2020 | 266 | 0.160 |
Why?
|
| Aneuploidy | 1 | 2020 | 139 | 0.160 |
Why?
|
| Ovariectomy | 2 | 2012 | 166 | 0.150 |
Why?
|
| Obesity | 2 | 2020 | 2330 | 0.150 |
Why?
|
| Testis | 1 | 2020 | 406 | 0.140 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 58 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2017 | 60 | 0.130 |
Why?
|
| Overweight | 1 | 2020 | 370 | 0.130 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2014 | 89 | 0.130 |
Why?
|
| Amino Acids | 1 | 2019 | 615 | 0.120 |
Why?
|
| Testosterone Propionate | 1 | 2015 | 3 | 0.120 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 32 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2022 | 1649 | 0.120 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 62 | 0.120 |
Why?
|
| Mice | 3 | 2022 | 17585 | 0.120 |
Why?
|
| Flutamide | 1 | 2014 | 27 | 0.110 |
Why?
|
| Estrous Cycle | 1 | 2014 | 35 | 0.110 |
Why?
|
| Mesenteric Arteries | 1 | 2014 | 50 | 0.110 |
Why?
|
| Receptors, Progesterone | 2 | 2009 | 663 | 0.110 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2014 | 20 | 0.110 |
Why?
|
| Vasoconstriction | 1 | 2014 | 92 | 0.110 |
Why?
|
| Uterine Artery | 1 | 2014 | 25 | 0.110 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 2 | 0.110 |
Why?
|
| Pregnancy, Prolonged | 1 | 2013 | 3 | 0.110 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 7 | 0.110 |
Why?
|
| Cervical Ripening | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ovulation | 1 | 2014 | 107 | 0.110 |
Why?
|
| Neuropeptides | 1 | 2014 | 113 | 0.110 |
Why?
|
| Models, Animal | 1 | 2016 | 452 | 0.110 |
Why?
|
| GTPase-Activating Proteins | 1 | 2014 | 85 | 0.100 |
Why?
|
| Angiotensin II | 1 | 2014 | 133 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2017 | 1538 | 0.100 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 58 | 0.100 |
Why?
|
| Vasodilation | 1 | 2014 | 174 | 0.100 |
Why?
|
| Oxygen Consumption | 2 | 2024 | 299 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2016 | 475 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 542 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2012 | 648 | 0.100 |
Why?
|
| HL-60 Cells | 1 | 2012 | 31 | 0.090 |
Why?
|
| Pertussis Toxin | 1 | 2012 | 21 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2014 | 1306 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 50 | 0.090 |
Why?
|
| Propionates | 1 | 2012 | 33 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2013 | 285 | 0.090 |
Why?
|
| Piperidines | 1 | 2013 | 224 | 0.090 |
Why?
|
| Weight Gain | 1 | 2014 | 377 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 460 | 0.090 |
Why?
|
| Nitriles | 1 | 2012 | 149 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 2772 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1593 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 350 | 0.090 |
Why?
|
| Ligands | 1 | 2012 | 477 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 930 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 291 | 0.080 |
Why?
|
| Embryo Implantation | 2 | 2008 | 223 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2009 | 67 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2012 | 327 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2902 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1002 | 0.070 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2008 | 17 | 0.070 |
Why?
|
| Endometrium | 2 | 2008 | 265 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 2313 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 576 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 52 | 0.060 |
Why?
|
| COS Cells | 1 | 2006 | 244 | 0.060 |
Why?
|
| Response Elements | 1 | 2006 | 99 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2006 | 306 | 0.060 |
Why?
|
| Mitochondria, Muscle | 1 | 2024 | 36 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2008 | 869 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4409 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3680 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12328 | 0.050 |
Why?
|
| Cytochromes b | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 272 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 1596 | 0.050 |
Why?
|
| Adipocytes | 1 | 2023 | 167 | 0.050 |
Why?
|
| Gene Expression | 2 | 2019 | 1485 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2023 | 232 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2582 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 549 | 0.040 |
Why?
|
| Follicular Phase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Cumulus Cells | 1 | 2019 | 44 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 130 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 1225 | 0.030 |
Why?
|
| Kinetics | 1 | 2019 | 1090 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2015 | 53 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2008 | 1014 | 0.030 |
Why?
|
| C-Peptide | 1 | 2015 | 93 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 146 | 0.030 |
Why?
|
| Corpus Luteum | 1 | 2014 | 25 | 0.030 |
Why?
|
| Pancreas | 1 | 2015 | 215 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2014 | 36 | 0.030 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2013 | 4 | 0.030 |
Why?
|
| Calgranulin B | 1 | 2013 | 9 | 0.030 |
Why?
|
| Furin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Peptide Hormones | 1 | 2014 | 70 | 0.030 |
Why?
|
| Acetylcholine | 1 | 2014 | 82 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2013 | 21 | 0.030 |
Why?
|
| Granulosa Cells | 1 | 2014 | 139 | 0.030 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2013 | 5 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2013 | 8 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2013 | 153 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 108 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 108 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 111 | 0.020 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 207 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 947 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 330 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 970 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1207 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1805 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3303 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2389 | 0.020 |
Why?
|
| Epithelium | 1 | 2007 | 335 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1559 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1757 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 6093 | 0.010 |
Why?
|
| Adult | 2 | 2013 | 30254 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 9616 | 0.010 |
Why?
|